General Studies
Pharmacokinetics
Efficacy
Resistance
Drug/Drug Interactions
Drug Comparison Studies
Adverse Events
Therapeutic Strategies

• FULL-TEXT DOCUMENT
  E;vitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/COBI/FTC/TAF) (Genvoya) Fixed-Dose Combination, Oral Tablet) [Internet].
  Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov.
  Internet Document

• Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
  Gallant JE, Koenig E, Andrade-Villanueva JF, et al  
  J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):338-340.
  Abstract
• FULL-TEXT ARTICLE
  An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
  M Llibre J, Raffi F, Moyle G, Behrens G, et al
  PLoS One. 2016 May 19;11(5):e0155406.
  Paper
• Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
  Ramanathan S, Custodio JM, Wei X, et al J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):281-8.
• .Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials.
  Reeves I, Fisher M, Kegg S,  et al
  J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19807.
  Abstract
• Which Patients have Greatest Need for Elvitegravir/Cobicistat/Emtricitabine/TenofovirDF-Based Therapy?
  Di Biagio A, Prinapori R, Taramasso L, et al 
  Recent Pat Antiinfect Drug Discov. 2014 Jul 16.
  Abstract
• Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US.
  Juday T, Correll T, Anene A, Broder MS,  et al
  Clinicoecon Outcomes Res. 2013 Sep 2;5:437-45.
  Abstract
• Stribild® (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate): A New Paradigm for HIV-1 Treatment.
  Manzardo C, Gatell JM.
  AIDS Rev. 2014 Jan-Mar;16(1):35-42.
• Abstract
• Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US.
  Juday T, Correll T, Anene A, Broder MS,  et al
  Clinicoecon Outcomes Res. 2013 Sep 2;5:437-45.
  Abstract
• FULL-TEXT ARTICLE
  Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate tablets.
  Cada DJ, Torres S, Levien TL, Baker DE.
  Hosp Pharm. 2013 Jan;48(1):48-56.
  Paper
• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment (December).
  Olin JL, Spooner LM, Klibanov OM.
  Ann Pharmacother. 2012 Nov 7
  Abstract
• Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.
  [No authors listed] Prescrire Int. 2013 Oct;22(142):233-5
• Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
  Schrijvers R, Debyser Z.
  Expert Opin Pharmacother. 2012 Sep;13(13):1969-83.
  Abstract
• The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.
  Marchand C.|
  Expert Opin Investig Drugs. 2012 May 10
  Paper
• Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment.
  Llibre JM, Clotet B. AIDS Rev. 2012 Jul;14(3):168-78.
  Abstract

• Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
  Mayer KH, Jones D, Oldenburg C,  et al
  J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):535-539.
  Abstract
• FULL-TEXT ARTICLE
  Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
  Llibre JM, Raffi F, Moyle G, et al PLoS One. 2016 Jul 8;11(7):e0159286.
  Paper
• Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
  Adams JL, Byrne D, Pepe R, Gray A, Baxter JD.
  Antivir Ther. 2016;21(2):175-80.
  Abstract
• Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS.
  Prinapori R, Di Biagio A.
  Patient Prefer Adherence. 2015 Aug 24;9:1213-8.
  Abstract
• Stribild: a review of component characteristics and combination drug efficacy.
  Murrell DE, Moorman JP, Harirforoosh S.
  Eur Rev Med Pharmacol Sci. 2015 Mar;19(5):904-14.
  Abstract
• The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.
  Raffe S, Fisher M.
  Opin Drug Metab Toxicol. 2015 Jan 2:1-9
  Abstract
• Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-Infected Patients with Mild to Moderate Renal Impairment.
  Post FA, Winston J, Andrade-Villanueva JF, et al
  J Acquir Immune Defic Syndr. 2014 Dec 2.
  Abstract
• Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.
  Arribas J, Rizzardini G, Arasteh K,  et al
  J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19805.
  Abstract
• FULL-TEXT ARTCLE
  Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years.
  Gazzard B, Girard PM, Di Perri G, et al
  J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19767.
  Paper
• The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study.
  Rokx C, Blonk M, Verbon A,  et al
  J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19789
  Abstract
• Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Review of Its Use in HIV Infection.
  Deeks ED.
  Drugs. 2014 Oct 29.
  Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.
  Arribas J, Rizzardini G, Arasteh K,  et al
  J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19805.
  Abstract
• Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor
  with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label,
  phase 3b, non-inferiority trial.
  Arribas JR, Pialoux G, Gathe J,  et al
  Lancet Infect Dis. 2014 Jun
  Abstract
• Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase
  inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised,
   open-label, phase 3b non-inferiority trial.
  Pozniak A, Markowitz M, Mills A,  et al.
  Lancet Infect Dis. 2014 Jun 4.
  Abstract
• Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1-Infected Subjects: 48 Weeks Data.
  Mills A, Crofoot G, Ortiz R, Rashbaum B, et al
  HIV Clin Trials. 2014 Mar-Apr;15(2):51-6.
  Abstract
• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Stribild): A Review of Its Use in the Management of HIV- Infection in Adults.
  Perry CM.
  Drugs. 2013 Dec 14.
  Abstract
• A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results.
  Zolopa A, Sax PE, Dejesus E,  et al
  J Acquir Immune Defic Syndr. 2013 May 1;63(1):96-100.
  Abstract
• Indirect treatment comparison of efficacy, safety and resistance of EVG/COBI/FTC/TDF (Quad) vs. RAL+FTC/TDF in treatment-naïve HIV patients.
  Dejesus E, Felix J, Vandewalle B, et al
  J Int AIDS Soc. 2012 Nov 11;15(6):18239.
  Abstract
• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment (December).
  Olin JL, Spooner LM, Klibanov OM.
  Ann Pharmacother. 2012 Nov 7|
  Abstract
• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
  Sax PE, DeJesus E, Mills A, Zolopa A, et al
  Lancet. 2012 Jun 30;379(9835):2439-48.
  Abstract
• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
  DeJesus E, Rockstroh JK, Henry K,  et al
  Lancet. 2012 Jun 30;379(9835):2429-38.
  Abstract
  Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir
  disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
  Cohen C, Elion R, Ruane P, et al
  AIDS. 2011 Mar 27;25(6):F7-F12
  Abstract